JPRN-UMIN000003508已完成未知
Phase I/II clinical study of WT1 peptide-based immunotherapy combined with Imatinib for chronic myelogeneous leukemia - Phase I/II clinical study of WT1 peptide-based immunotherapy combined with Imatinib for CM
Department of Cancer immunotherapy, Osaka University Graduate School of Medicine0 个研究点目标入组 30 人开始时间: 2010年4月19日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 16years-old 至 80years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1. Post allogeneic hematopoietic stem cell transplantation 2. There is deep-seated active infection. 3. There are severe complications including malignant hypertention, cardiac failure, liver cirrhosis, severe DM, severe lung fiblosis, active interstitial pneumonitis. 4. Patients who have complications that are considered inappropriate for the trial. 5. Pregnant or lactating woman 6. There is severe psychiatric disorder. 7. There are other active malignancies. 8. Responsible doctors judged the patient inappropriate for the trial.
研究者
相似试验
已完成
1 期
Phase I clinical study of a WT1-W10 peptide immunotherapy combined with standard treatment against diffuse midline glioma (WT1-TR-DMG).glioblastoma multiformeJPRN-UMIN000025452Cancer Vaccination Therapy Research Network Central Office, Department of Immunology, Kochi Medical School10
已完成
1 期
Fhase I clinical study of WT1 petide-based immnotherapy using WT1 helper peptide for recurrent malignant gliomaRecurrent malignant gliomaJPRN-UMIN000003506Department of Cancer immunotherapy, Osaka University Graduate School of Medicine18
已完成
1 期
Phase I/II clinical trial of WT1 peptide-based vaccine for the patients with malignant tumors.Malignant solid tumors, Malignant lymphoma, Multiple Myeloma, Acute leukemiaJPRN-UMIN000002001Department of Cancer immunotherapy, Osaka University Graduate School of Medicine30
已完成
不适用
Phase II clinical trial of WT1 peptide-based vaccine combined with Temozoromide for patients with glioblastoma.GlioblastomaJPRN-UMIN000026965Department of Cancer Immunotherapy, Osaka University Graduate School of Medicine35
尚未招募
1 期
Phase II clinical trial of WT1 peptide-based vaccine for pediatric patients with recurrent malignant gliomaMalignant Glioma DIPGJPRN-UMIN000013258Osaka university graduate school of medicine18